Peptide receptor radionuclide therapy for the treatment of pancreatic neuroendocrine tumors: Recent insights

Jason S. Starr; Mohamad Bassam Sonbol; Timothy J. Hobday; Akash Sharma; Ayse Tuba Kendi; Thorvardur R. Halfdanarson

doi:10.2147/OTT.S202867

Peptide receptor radionuclide therapy for the treatment of pancreatic neuroendocrine tumors: Recent insights

Jason S. Starr, Mohamad Bassam Sonbol, Timothy J. Hobday, Akash Sharma, Ayse Tuba Kendi, Thorvardur R. Halfdanarson

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

Peptide receptor radionuclide therapy (PRRT) is a paradigm shifting approach to the treatment of neuroendocrine tumors. Although there are no prospective randomized trials directly studying PRRT in pancreatic neuroendocrine tumors (panNETs), there are data to suggest benefit in this patient population. Collectively, the data, consisting of two prospective and six retrospective studies, show a median PFS ranging from 20 to 39 months and a median OS ranging from 37 to 79 months. There are ongoing (and upcoming) prospective, randomized trials of PRRT in panNETs, which will provide further evidence to support this approach.

Original language	English (US)
Pages (from-to)	3545-3555
Number of pages	11
Journal	OncoTargets and Therapy
Volume	13
DOIs	https://doi.org/10.2147/OTT.S202867
State	Published - 2020

Keywords

PRRT
PanNET
Pancreatic neuroendocrine tumor
Peptide receptor radionuclide therapy
Theranostics

ASJC Scopus subject areas

Oncology
Pharmacology (medical)

Access to Document

10.2147/OTT.S202867

Cite this

@article{a8e8f6516fbc4d019ddc7d3af20004fb,

title = "Peptide receptor radionuclide therapy for the treatment of pancreatic neuroendocrine tumors: Recent insights",

abstract = "Peptide receptor radionuclide therapy (PRRT) is a paradigm shifting approach to the treatment of neuroendocrine tumors. Although there are no prospective randomized trials directly studying PRRT in pancreatic neuroendocrine tumors (panNETs), there are data to suggest benefit in this patient population. Collectively, the data, consisting of two prospective and six retrospective studies, show a median PFS ranging from 20 to 39 months and a median OS ranging from 37 to 79 months. There are ongoing (and upcoming) prospective, randomized trials of PRRT in panNETs, which will provide further evidence to support this approach.",

keywords = "PRRT, PanNET, Pancreatic neuroendocrine tumor, Peptide receptor radionuclide therapy, Theranostics",

author = "Starr, {Jason S.} and Sonbol, {Mohamad Bassam} and Hobday, {Timothy J.} and Akash Sharma and Kendi, {Ayse Tuba} and Halfdanarson, {Thorvardur R.}",

note = "Publisher Copyright: {\textcopyright} 2020 Starr et al.",

year = "2020",

doi = "10.2147/OTT.S202867",

language = "English (US)",

volume = "13",

pages = "3545--3555",

journal = "OncoTargets and Therapy",

issn = "1178-6930",

publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Peptide receptor radionuclide therapy for the treatment of pancreatic neuroendocrine tumors

T2 - Recent insights

AU - Starr, Jason S.

AU - Sonbol, Mohamad Bassam

AU - Hobday, Timothy J.

AU - Sharma, Akash

AU - Kendi, Ayse Tuba

AU - Halfdanarson, Thorvardur R.

PY - 2020

Y1 - 2020

N2 - Peptide receptor radionuclide therapy (PRRT) is a paradigm shifting approach to the treatment of neuroendocrine tumors. Although there are no prospective randomized trials directly studying PRRT in pancreatic neuroendocrine tumors (panNETs), there are data to suggest benefit in this patient population. Collectively, the data, consisting of two prospective and six retrospective studies, show a median PFS ranging from 20 to 39 months and a median OS ranging from 37 to 79 months. There are ongoing (and upcoming) prospective, randomized trials of PRRT in panNETs, which will provide further evidence to support this approach.

AB - Peptide receptor radionuclide therapy (PRRT) is a paradigm shifting approach to the treatment of neuroendocrine tumors. Although there are no prospective randomized trials directly studying PRRT in pancreatic neuroendocrine tumors (panNETs), there are data to suggest benefit in this patient population. Collectively, the data, consisting of two prospective and six retrospective studies, show a median PFS ranging from 20 to 39 months and a median OS ranging from 37 to 79 months. There are ongoing (and upcoming) prospective, randomized trials of PRRT in panNETs, which will provide further evidence to support this approach.

KW - PRRT

KW - PanNET

KW - Pancreatic neuroendocrine tumor

KW - Peptide receptor radionuclide therapy

KW - Theranostics

UR - http://www.scopus.com/inward/record.url?scp=85084069506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85084069506&partnerID=8YFLogxK

U2 - 10.2147/OTT.S202867

DO - 10.2147/OTT.S202867

M3 - Review article

AN - SCOPUS:85084069506

SN - 1178-6930

VL - 13

SP - 3545

EP - 3555

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

ER -

Peptide receptor radionuclide therapy for the treatment of pancreatic neuroendocrine tumors: Recent insights

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this